The original article identified the FDA compounding decision as the primary risk to JPMorgan's $35 price target. Amazon's GLP-1 entry changes the risk calculus — even if the FDA rules favorably on compounded semaglutide, Hims & Hers now faces a well-capitalized competitor with massive distribution reach and an existing healthcare infrastructure. Amazon's pricing power and customer base could pressure HIMS revenue growth estimates independent of any regulatory outcome.
Watch for two things: first, how Amazon prices and distributes its GLP-1 offerings relative to HIMS's current telehealth model; second, whether sell-side analysts begin revising revenue estimates or price targets to reflect the new competitive dynamic. The bull case for HIMS now requires clearing both the FDA hurdle and the Amazon threat simultaneously.
Hims & Hers Health Gets JPMorgan's Blessing at $35 — But the FDA Holds the Real Vote
NEW YORK, April 26 —
JPMorgan initiated coverage of Hims & Hers Health (HIMS) at Overweight with a $35 price target, about 15% above the current $30.56.
- JPMorgan's $35 target sits about 15% above the current $30.56 share price
- HIMS trades at 22.2x forward earnings on $2.3bn in trailing twelve-month revenue
- FDA enforcement decisions on compounded GLP-1 medications will determine whether the bull case survives
What Actually Happened
Two things landed in the same news cycle. That's not a coincidence. JPMorgan initiated HIMS with an Overweight rating, and Eli Lilly expanded its LillyDirect partnership to deepen Hims & Hers' GLP-1 weight loss offerings. The Lilly deal matters more than the analyst note. A direct commercial relationship with the company that makes tirzepatide gives HIMS a path to selling branded GLP-1 drugs — not just compounded versions sitting in a regulatory gray zone. JPMorgan's initiation reads like a vote of confidence in that exact pivot. Analysts don't typically hand Overweight ratings to companies whose core product might get pulled by a regulator.
The Catch
The entire GLP-1 thesis for HIMS rests on a question nobody at JPMorgan or Eli Lilly can answer: what will the FDA do about compounded semaglutide? The agency has been tightening its stance on compounding pharmacies selling knockoff versions of Novo Nordisk's Ozempic and Wegovy. If FDA enforcement shuts down compounded GLP-1s, a large chunk of HIMS revenue disappears overnight.
The Lilly partnership is partly a hedge against exactly that outcome — a way to stay in the weight loss business through the front door instead of the side entrance. But the transition isn't free. Branded drugs carry lower margins than compounded ones. HIMS would go from being the low-cost provider to being a distribution channel for someone else's product. At 22.2x forward earnings, the stock is priced for things going mostly right.
Bottom Line
This is a better setup than HIMS had six months ago. JPMorgan coverage and a deeper Lilly relationship remove two risks: obscurity and supplier dependency. But the stock is still a binary bet dressed up as a growth story. If the FDA cracks down hard on compounding, the Lilly partnership becomes a lifeline, not a growth lever. If compounding stays legal, the partnership is pure upside. The number to watch: GLP-1 revenue contribution in the next earnings report. That tells you how exposed the company really is to a single regulatory decision.
There's no existing Basis Report for HIMS yet. Generate a free HIMS investment report here.
Basis Report does not hold positions in securities discussed. This is not investment advice.